Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment

    NEXT STORY
    CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program
    PREV STORY
    Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors

    MIAMI, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on ...

    author_avatar
    NASDAQ Market News

    GILEAD EN GALAPAGOS PRESENTEREN NIEUWE DATA OVER FILGOTINIB OP HET JAARLIJKSE ACR/ARP 2019 CONGRES

    author_avatar
    NASDAQ Market News

    Elsalys Biotech : New studies confirm anti-CD160 potential in ophthalmology

    New studies confirm anti-CD160 antibodies are potential therapeutics for ophthalmic diseases Efficacy and safety ...

    author_avatar
    NASDAQ Market News